112-20 | The Effect of CFTR Modulator Trikafta on Lower Airway Microbiome in Cystic Fibrosis Patients

Trial Number

112-20

Condition

Cystic Fibrosis

Participant Age Range

All ages

Participant Gender

Any

Enrolling Participants

Yes

Overview

“The effect of CFTR Modulator Trikafta (Elexacaftor/ivacaftor/tezacaftor) on lower airway microbiome in Cystic Fibrosis patients”

Efficacious CFTR modulation may contribute to lower frequency of culture positivity for Pseudomonas aeruginosa and other respiratory pathogens, particularly in Cystic Fibrosis patients with less established disease. Studies have shown that patients receiving lumacaftor/ivacaftor for CF had significantly delayed acquisition of P. aeruginosa and Staphylococcus aureus. These studies suggest that the existing CFTR modulators, particularly ivacaftor, favorably impact CF microbiology, but the durability of these effects is currently uncertain.